Sign In
Buy SVA
$6.47
+0 (+0%)
At Close: Feb 07, 2020
Sinovac Reports Unaudited Third Quarter 2020 Financial Results
07:30am, Monday, 07'th Dec 2020
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial re
China's Sinovac To Double Covid-19 Vaccine Output Anticipating Regulatory Approval
07:07am, Monday, 07'th Dec 2020
The company hopes to produce 600 million doses of its CoronaVac vaccine a year, enough for 300 million people.
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
06:30pm, Sunday, 06'th Dec 2020
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Sinovac Life Sciences
Sinovac's Covid-19 Vaccine Appears Safe And Prompts ‘Quick' Immune Response, Study Finds
07:41am, Wednesday, 18'th Nov 2020
Researchers believe the vaccine, which is already approved in China, could be “suitable for emergency use during the pandemic,” though further clinical trials will be needed.
Sinovac COVID-19 Vaccine Trial Halted In Brazil Over Adverse Event
03:31am, Tuesday, 10'th Nov 2020
Brazilian health regulator has decided to halt clinical trials of a frontrunning Chinese vaccine following a “severe adverse event” observed in a participant, Bloomberg reported Monday.
